The FDA has approved Nasacort (triamcinolone acetonide; Sanofi Aventis) Allergy 24hr nasal spray as an over-the-counter (OTC) treatment for seasonal and perennial nasal allergies in adults and children 2 years of age and older.
Triamcinolone acetonide is a corticosteroid that has been shown to have a wide range of actions on multiple cell types (eg, mast cells, eosinophils, neutrophils, macrophages, lymphocytes) and mediators (eg, histamine, eicosanoids, leukotrienes, cytokines) involved in inflammation.
Nasacort Allergy 24hr nasal spray will be marketed by Chattem, Sanofi’s consumer health division. Nasacort Allergy 24hr nasal spray will be available in 60- and 120-metered dose sprays.
Chattem anticipates that Nasacort Allergy 24hr nasal spray will be available in Spring 2014.
For more information call (423) 821-4571 or visit Nasacort.com.